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Abstract: A branching double annulation cascade (BDAC) strategy for diverse and complex fused 
THIQ scaffolds via a highly reactive iminium induced one-pot double cyclization sequence 
involving Pictect-Spengler type cyclization has been developed for the first time. The salient 
features of this protocol are direct and rapid access to unprecedented diverse fused THIQ 
skeletons, metal/catalyst free, cleaner reaction profile, good to excellent yields and convenient 
approach. This catalyst-free domino process facilitates the double annulation with variety of 
scaffold building agents via two C-N and one C-X (X = C, N, O) bonds formation in a single step, 
under uniform reaction conditions. Furthermore, we reveal an unusual dual BDAC sequence 
leading to N-N linked isoquinoline dimer. 
Introduction  
The pursuit of identification of new small molecule modulators for chemical genetics and drug 
discovery has led to synthesis of natural product based compounds, combinatorial synthesis of libraries1 
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and cascade strategies.2 Awestruck by the nature’s ability to create structurally and functionally diverse 
pre-validated natural product libraries from a limited pool of simple building blocks and the demand for 
compound libraries with structural complexity and stereogenic centers3 has led synthetic organic chemist 
to explore chemical space paradigm by taking the leads from natural products, which is highly 
challenging.4 To meet this challenge, diversity oriented synthesis (DOS)5 has emerged as an important 
tool which entails efficient synthesis of skeletally, stereochemically and functionally diverse libraries.6 
DOS by employing folding7/branching pathways,8 build/couple/pair (B/C/P) strategies,9 structural 
variations in common substrates/building blocks10 and branching cascade approaches11 have successfully 
demonstrated in creating diverse molecular scaffolds, which serve as biological probes and potential leads 
for drug discovery. 
In connection with our broader interests in developing synthetic strategies for diverse and complex 
polyheterocycles involving cascade annulations12 in a one-pot manner, herein, we are pleased to disclose 
a cascade sequence involving a highly reactive iminium intermediate and further Pictet-Spengler13 type 
cyclization for accessing three dimensional privileged THIQ compounds as branching double annulation 
cascade (BDAC). 
Numerous strategies have been reported for the synthesis of THIQ such as Strecker 
lactamization/alkylations,14 allylation-lactamization cascade,15 Mukaiyama-Mannich lactamization/ 
alkylations,16 1,3-dipolar cycloaddition reaction of azomethine imine17 and Grignard18 as well as 
allyltrimethoxysilane19 addition to imine as shown in Scheme 1a. Latest approaches to substituted THIQ 
involve metal catalysed ortho C-H allylation/cyclization (Scheme 1b),20 cross-dehydrogenative coupling 
(CDC) reactions (Scheme 1c),21 and redox-neutral reactions.22 Recently, we have developed cascade 
strategies for the synthesis of THIQ in one-pot fashion.12c,d However, many of the previous reported 
approaches to construct complex THIQ derivatives often have limited skeletal diversity and require 
several steps, and hence there lies a need to develop efficient strategies for THIQ compounds. To address 
this challenge, we envisioned that the concept of branching cascade could be utilized, involving the 
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reaction of a common substrate with different scaffold-building agents (SBAs) and Scheme 1d illustrates 
the general concept of substrate-based approach to scaffold diversity, which we have utilized in the 
present strategy. To the best of our knowledge the branching cascade pathway has not yet been reported 
for the synthesis of diverse and complex THIQ molecules. With this in mind, we have identified 2-(2-
bromoethyl)benzaldehyde 1a as a common substrate to generate highly reactive and versatile iminium 
Scheme 1. Different approaches for the synthesis of fused THIQ skeletons and our designed BDAC 
strategy. 


















































































intermediate for further diversification with wide range of SBAs 2 (Scheme 1e).  THIQ with a stereogenic 
center at the C1 position occupy an important place among natural and unnatural compounds possessing 
valuable biological activities23 and are precursors for synthesis of complex alkaloids.14-16  
       Herein, we report a novel BDAC strategy for rapid access to diverse molecular library containing 
unprecedented THIQ fused skeletons by using 2-(2-bromoethyl)benzaldehyde 1a as a common substrate 
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and variety of N,C-, N,O- and N,N-1,5-bisnucleophiles as SBAs. The synthesized molecules contain 
multiple privileged structures such as tetrahydroisoquinoline (coralydine I and (+) cripsin A II), 
imidazoquinoxaline (PPQ-102 III),24 pyrroloquinoxaline (IV),25 tetrazolo[1,5-c]quinoxaline (V),26 
quinazolinone (rutaecapine VI),27 and benzothiadiazinedioxide (IDRA-21 VII),28 which form part of 
natural products and biological important molecules (Figure 1). 
 
Figure 1. Naturally occurring THIQ alkaloids and representative examples of bioactive molecules 
containing our privileged motifs. 
Results and Discussion: 
To this end, initially to check the feasibility of our branching cascade strategy we performed a model 
reaction of 2-(2-bromoethyl)benzaldehyde (1a) with 2-(2-aminophenyl)imidazole (2a) under polar protic 
solvents such as MeOH and EtOH at various temperatures (Table 1, entries 1-4), of which under reflux 
temperature in MeOH gave the desired product 3a albeit in 47% yield (Table 1, entry 2). Inspired by this 
result, in order to increase the yield further, we screened the reaction under polar aprotic solvents such as 
acetonitrile and 1,4 dioxane, which afforded the moderate yields of the products (20-53%, Table 1, entries 
5-7). We continued our attempts to optimize the yield by performing the reaction in chlorinated solvents 
(Table 1, entries 8-10) and to our delight, DCE at reflux temperature provided the desired product in good 
yield (Table 1, entry10). After having screened various solvents, we have chosen DCE as a solvent for 
further optimization studies. The increase in reaction temperature to 90 oC resulted in better yield of the 
product 3a (75%) (Table 1, entry 11), however, further increase in temperature to 100 oC as well as the 
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unconventional microwave heating could not improve the yield of the product further (Table 1, entries 12 
and 13). Our attempts to use additives like DBU, PTSA and Et3N have failed to improve the yield of the 
product (Table 1, entries 14-16). Similarly, employing dehydrating agents like 4Å molecular sieves and 
Na2SO4 did not aid in enhancing the yields (Table 1, entries 17 and 18).   





Entry Solvent Additive Tempt oC Time (min) Yield (%)b 
1 MeOH - rt 120 45 
2 MeOH - reflux 60 47 
3 EtOH - rt 120 40 
4 EtOH - reflux 60 42 
5 CH3CN - rt 90 20 
6 CH3CN - reflux 60 53 
7 1,4-Dioxane - reflux 60 45 
8 DCM - rt 90 42 
9 DCE - rt 90 56 
10 DCE - reflux 60 66 
11 DCE - 90  30 75c 
12 DCE - 100  30 65 
13 DCE - 90  30 66d 
14 DCE DBU 90  60 0 
15 DCE PTSA 90  60 70 
16 DCE Et3N 90  60 68 
17 DCE M.S. 90  60 70e 
18 DCE Na2SO4 90  60 69 
 
a Reaction conditions: 1a (0.23 mmol), 2a (0.23 mmol) and 1 mL of solvent; b Isolated yields after column 
chromatography; c No detrimental effect observed on reaction outcome by varying the concentration of 
reaction. d Unconventional microwave heating was used;  e 4Å molecular sieves was used. 
 
At the outset of this study, our efforts were directed towards design and synthesis of different N,C-, 
N,O-, and N,N-1,5-bisnucleophiles (Figure 2). With this pool of compounds (2a-2h) in hand, a series of 
annulation reactions were envisaged in order to achieve skeletal diversity. With the standard reaction 
conditions in hand, we first subjected substituted imidazole based N,C-bisnucleophiles 2a(I) and 2a(II) 
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leading to corresponding products 3b and 3c in 67% and 68% yields.  In addition, we have also employed 
2-(1H-pyrrol-1-yl)aniline (2b) in our cascade annulation resulting in pyrroloquinoxaline-THIQs (3d-3f) in 
good yields (71-73%). The fact that the more nucleophilic pyrrole substituted SBA 2b gave better yield 
than imidazole substituted SBA 2a is in agreement with our proposed concept. In our efforts to diversify 
the skeleton, we investigated azole based N,N-bisnucleophiles such as 2c and 2d, which resulted in the 
corresponding products tetrazoloquinozalino-THIQs (3g-3i, 75-87%) and benzimidazoquinazolino-
THIQs (3j and 3k, 48% and 65%). Tetrazole based SBA 2c was the best nucleophile, which afforded the 
excellent yields of the corresponding products among all heterocyclic SBAs. With an aim to functionally 
diversify the skeleton and for comparative study, we evaluated the reactivity of the amide as N,N-
bisnucleophile, in our present strategy. To our surprise the reaction of variety of 2-aminobenzamides 2e 
with 1a-1c under standard conditions, afforded the corresponding products (3l-3s) in good to high yields 
(48-70%). It is to be noted that these products could be diversified further for various applications. The 
successful employment of 2-aminobenzamides 2e (I-V), prompted us to examine the 2-
aminobenzenesulfonamides (2f) as a scaffold building agent for the synthesis of 
tetrahydrobenzothiadiazinoisoquinolino-6,6-dioxide which is a privileged scaffold present in several 
natural products of biological interest.28 Accordingly, when we have reacted variety of 2-
aminosulphonamides (2f) with 1a-1c, afforded the products 3t-3z in good to excellent yields (62-90%).  
Encouraged by the results, we envisioned to explore the nucleophilicity of oxygen in our present 
strategy, by treatment of 2-aminobenzyl alcohol 2g(I) and 2-aminobenzoic acid 2g(II) with 1a, which 
afforded 3aa and 3ab in 60 and 72% yields, respectively. Due to the ubiquity of THIQ based natural 
products containing C1 stereocenter, many research groups have focused on the introduction of a 
substituent at C1 position in a stereogenic fashion and also on natural products containing two contiguous 
and 1,3 stereocenters. Our aim to introduce stereochemical diversity in our present strategy, prompted us 
to examine the possibility of diastereoselectivity by employing the 1,3 stereocenter inducing SBAs. With 
this idea in mind, we selected the phenyl substituted secondary alcohol 2g(III) as N,O-1,5 bisnucleophile, 
which afforded the expected product 3ac although in low stereoselectivity (cis/trans = 4:3) as a mixture  
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3d, R1 = H, R2 = H, 71%
3e, R1 = CH3, R2 = H, 60%
3f, R1= Br, R2 = H, 73%
3a, R1 = H, R2 = H, 72%
3b, R1 = H, R2 = CH3, 67%
3c, R1 = Br, R2 = H, 68%
3t, R1 = H, R2 = H, 70%
3u, R1 = H, R2 = Cl, 90%
3v, R1 = H, R2 = Br, 82%
3w, R1 = H, R2 =I, 79%
3x, R1 = CH3, R2 = H, 62%
3y, R1 = CH3, R2 = I, 68%
3j, R1 = H, R2 = H, 65%
3g, R1 = H, R2 = H, 87%
3h, R1 =CH3, R2 = H, 68%
3i, R1 = Br, R2 = H, 75%
3aa, X = CH2,R1 = H, R2 = H, 60%








1a, R1 = H
1b, R1 = CH3






3k, R1 = CH3, R2 = H, 48%



















3ac, X = CHPh, R1 = H, R2 = H, 52%, cis/trans= 4:3 dr
c
3n, R1 = H, R2 = H, R3 = Ph, 70%
3p, R1 = H, R2 = Cl, R3 = Bn, 55%
3q, R1 = CH3, R2 = H, R3 = Bn, 60%
3r R1 = CH3, R2 = Cl, R3 = Bn, 48%
3s, R1 = Br, R2 = H, R3 = Bn, 62%
3o, R1 = H, R2 = H, R3 = Bn, 65%
3l, R1 = H, R2 = H, R3 = PhNH, 62%




























2a(I) R2 = H 2d
2f(I)R2 = H
2c
2a(II) R2 = CH3
2g(I) X = CH2
2b
2g(II) X = CO2f(II)R2 = Cl
2f(III)R2 = Br
2f(IV)R2 = I
2e(I)= R2 = H, R3 = Ph-NH
2e(II)= R2 = Cl, R3 = Ph-NH
2e(III)= R2 = H, Ph
2e(IV) = R2 = H, R3 = Bn
2e(V)= R2 = Cl, R3 = Bn
2g(III) X = CHPh
1 gm scale = 0.79 gm, 56%
                 
 
a Reactions were performed in DCE (1mL) with 1 (0.23 mmol), 2 (0.23 mmol) at 90 oC for 30-60 min.  b 
2a-2g represent various  N,C-, N,O- and N,N-1,5-bisnucleophiles as SBAs. 
c dr was determined by 1H 
NMR spectroscopy. 
 
Figure 2. Synthesis of various diverse fused tetrahydroisoquinoline compounds 3a-3ac through 
branching double annulation cascade (BDAC) strategy. 
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of inseparable diastereomers in 52% yield. The relative configuration of the major diastereomers was 
assigned to be cis based on NOE experiment. Our attempts to improve the diastereoselectivity by varying 
temperature, solvent system and concentration went in vein (see ESI). All the compounds were confirmed 
by 1H and 13C spectroscopy and high resolution mass spectrometry. Although, the NMR spectroscopic 
data support the formation of fused privileged tetrahydroisoquinoline scaffolds 3, the structures of 3p and 
3t were unambiguously secured by X-ray crystal analyses (see ESI for X-ray data of 3p and 3t).  
In our present BDAC strategy, several diverse halo-substituted compounds have been synthesized, 
which could be utilized as versatile synthons for further diversification.  The present BDAC strategy was 
proved to be very general and versatile by enabling variety of SBAs with distinct nucleophilic centers to 
react with common precursor under unified reaction conditions. Overall, it was found that the N,N-
bisnucleophiles afforded excellent yields compared to N,C and N,O-bisnucleophiles, and 2-
aminobenzenesulfonamides (2f) though being weak nucleophile comparatively were the best among all 
1,5-bisnucleophiles in terms of the reactivity and yield. The substituents such as Me and Br on common 
substrate 1 was non detrimental on reaction outcome and yield of the products (3a-3ac).  
Scheme 2. Scope of BDAC strategy with 2-aminobenzohydrazide (2h). 
 
Further aiming to expand the diversity in the BDAC strategy, we envisioned that by using 2-
aminobenzohydrazide (2h) as 1,6-bisnucleophile can result in 7-membered fused 
tetrahydrobenzotriazepino isoquinolinone skeleton. To our surprise, when we used 2-
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aminobenzohydrazide (2h) as N,N-bisnucleophile, resulted in the dimer product 3ae instead of expected 
compound 3ad (Scheme 2), which was confirmed by spectral and X-ray crystal structure analyses (CCDC 
1478494, see ESI for X-ray data of 3ae). The formation of 3ae can be explained by dual BDAC reactions 
involving transamination of 2h with intermediate A with the elimination of hydrazine hydrobromide. 
   After having developed the BDAC strategy for the synthesis of diverse heterocyclic scaffolds, we 
envisaged that it would be appropriate to check the scalability of our BDAC strategy for the synthesis of 
fused tetrahydroisoquinoline compounds 3. Accordingly, we performed the scale-up (1g scale) reaction 
for the synthesis of the product 3o, resulting in 0.79 gm, 56% yield (Figure 2).   
Based on the literature reports12c,d, 29 and experimental studies (see ESI for experimental studies), we 
have formulated a plausible reaction mechanism for the synthesis of diverse fused tetrahydroisoquinoline 
derivatives as shown in scheme 3. Initially, 2-(2-bromoethyl)benzaldehydes (1a) and scaffold-building 
agents (SBAs) 2 react to give an imine intermediate I, followed by an intramolecular alkylative 
cyclization leading to reactive Mannich base II which on further Pictet-Spengler13 type annulation affords 
the desired product 3 (Scheme 3).    
Scheme 3. Plausible reaction mechanism for the synthesis of THIQ fused compound 3. 
 
In summary, we have successfully developed an advanced metal-free double annulation branching 
cascade (BDAC) strategy for the synthesis of library of 29 new, complex and diverse 
tetrahydroisoquinoline fused derivatives by using a variety of N,C-, N,O- and N,N-1,5-bisnucleophiles as 
a SBAs and 2-(2-bromoethyl)benzaldehydes as a common precursor under uniform reaction conditions. 
The important features of the present protocol are metal and catalyst-free, operational simplicity, use of 
simple starting materials and moderate to excellent yields. Moreover, the success of gram-scale synthesis 
of fused THIQ make this process useful for industrial applications. Undoubtedly, this protocol which 
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affords three dimensional THIQ derivatives which are diverse in its coverage of chemical space, should 
prove useful for further scaffold innovation in drug discovery program. Further, studies on 
enantioselective synthesis of these scaffolds are currently under way. 
We gratefully acknowledge Council of Scientific and Industrial Research (CSIR), New Delhi, India 
and Indian Institute of Technology Hyderabad (IITH) for financial support. AHS, SMP and SV thank to 
UGC, New Delhi, India for the award of research fellowship. 
Experimental Section 
General Considerations 
      IR spectra were recorded on a FTIR spectrophotometer. 1H NMR spectra were recorded on 400 MHz 
spectrometer at 295 K in CDCl3; chemical shifts (δ ppm) and coupling constants (Hz) are reported in 
standard fashion with reference to either internal standard tetramethylsilane (TMS) (δH = 0.00 ppm) or 
CHCl3 (δH = 7.25 ppm). 
13C NMR spectra were recorded on 100 MHz spectrometer at RT in CDCl3; 
chemical shifts (δ ppm) are reported relative to CHCl3 [δC = 77.00 ppm (central line of triplet)]. In the 
1HNMR, the following abbreviations were used throughout: s = singlet, d = doublet, t = triplet, q = 
quartet, qui = quintet, m = multiplet and br s. = broad singlet. The assignments of signals were confirmed 
by 1H, 13C CPD, and DEPT spectra. High-resolution mass spectra (HR-MS) were recorded using Q-TOF 
multimode source.  Melting points were determined on an electro thermal melting point apparatus and are 
uncorrected. 2-(2-bromoethyl)benzaldehyde (1a-1c) were prepared by using known procedures. All the 
bisnucleophiles such as N,C-, N,O- and N,N-1,5-bisnucleophiles as a SBAs (2a-2h) which were either 
prepared in the laboratory or purchased from commercial sources. All the dry solvents such as, MeOH, 
EtOH and 1,4-Dioxane were dried over sodium metal and  CH3CN, DCM and DCE were dried over 
calcium hydride. 
All small scale dry reactions were carried out using standard syringe-septum technique. Reactions 
were monitored by TLC on silica gel using a combination of petroleum ether and ethyl acetate as eluents. 
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Reactions were generally run under argon atmosphere. Solvents were distilled prior to use; petroleum 
ether with a boiling range of 40 to 60 ˚C was used.  
(I) General Procedure 1: Preparation of isochromans.
30 
       A mixture of the substituted phenylethyl alcohol (i) (4.97 mmol), chloromethylmethyl ether (7.046 
mmol) and N,N-diisopropylethylamine (9.95 mmol)  in dry dichloromethane (15 mL)  was stirred under 
nitrogen atmosphere for 2.5 h at rt. The reaction mixture was then washed with water, dried (Na2SO4) and 
the solvent was removed in vaccuo.  The crude MOM acetal (ii) was dissolved in dried acetonitrile and 
added to cooled (0 oC) solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) (4.97 mmol).  The 
reaction was carried out under nitrogen atmosphere for 3h. Then the mixture was quenched by the 
addition of l M NaHCO3.  The organic phase was washed with brine, dried with anhydrous sodium 
sulphate and evaporated under reduced pressure. Purification by column chromatography afforded 
corresponding substituted isochromans (see ESI). 
(II) General procedure 2: Preparation of 2-(2-bromoethyl)benzaldehydes (1a-1c).
30
  
      To a solution of the substituted isochroman iii (7.46 mmol) derivatives in acetonitrile (15 mL), CuBr2 
(8.95 mmol) was added under nitrogen atmosphere. The solution was refluxed for about 2h and then 
cooled to room temperature.  The reaction mixture was added water, extracted with ethyl acetate.  The 
combined organic extracts were washed with brine and dried with anhydrous Na2SO4, filtered and 
concentrated and then purified by silica gel column chromatography to afford the products (1a-1c) in 68-
74% yield (see ESI). 
(III) General procedure 3: Synthesis of diverse scaffold containing fused tetrahydroisoquinolines 
(3a-3ae) through BDAC strategy: 2-(2-Bromoethyl)benzaldehydes (1a-c) (50 mg, 0.23 mmol) and 
variety of bisnucleophiles 2 (0.23 mmol) were taken in a 5 mL round bottom flask and added 1 mL of 
DCE heated at 90 oC. After completion of the reaction (monitored by TLC), the DCE solvent was 
completely evaporated under reduced pressure. The reaction mixture was quenched by aq. NaHCO3 and 
extracted with ethyl acetate (2 × 20 mL). The combined organic layer was washed with brine solution and 
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allowed to dry over anhydrous Na2SO4. The crude extract was purified by filtration through a silica gel 
(100-200 mesh) column using hexane and ethyl acetate as eluents to yield the desired product 3a-3ae.   
(IV) General procedure 4: Large scale synthesis of isoquinolinoquinazolinone 3o through BDAC 
strategy. 
2-(2-Bromoethyl)benzaldehyde (1a) (1000 mg, 4.69 mmol) and N,N-bisnucleophile 2e(IV) (790 mg, 4.69 
mmol) were taken in a 25 mL round bottom flask and added 10 mL of DCE heated at 90 oC. After 
completion of the reaction (monitored by TLC), the DCE solvent was completely evaporated under 
reduced pressure. The reaction mixture was quenched by aq. NaHCO3 and extracted with ethyl acetate (2 
× 20 mL). The combined organic layer was washed with brine solution and allowed to dry over 
anhydrous Na2SO4.  The crude extract was purified by filtration through a silica gel (100-200 mesh) 
column using hexane and ethyl acetate as eluents to yield the desired product 3o in 56%, 790 mg. 
Spectroscopic data of all unknown compounds: 7,11b-Dihydro-6H-imidazo-6H-imidazo[1,5-
a]isoquinolino[1,2-c]quinoxaline (3a): Brown solid (46 mg, 72%); mp 198−200 oC; IR (MIR-ATR, 
4000−600 cm-1): νmax = 3112, 2923, 2854, 1710, 1600, 1507, 1462, 1351, 1109, 746, 653; 
1H NMR (400 
MHz, CDCl3) δ ppm = 2.86 (d, J = 16.1 Hz, 1H), 3.21−3.28 (m, 1H), 3.36−3.40 (m, 1H), 3.97 (ddd, Ja = 
12.5, Jb = 5.4 and Jc = 2.2 Hz, 1H), 5.53 (s, 1H), 6.92−6.97 (m, 2H), 7.05 (d, J = 7.8 Hz, 1H), 7.17−7.23 
(m, 4H), 7.26−7.32 (m, 1H), 7.43 (dd, Ja = 7.8 and Jb = 1 Hz, 1H), 8.0 (s, 1H); 
13C NMR (100 MHz, 
CDCl3) δ ppm = 27.1, 43.7, 54.7, 114.7, 115.7, 119.7, 124.6, 124.7, 126.3, 126.9, 127.4, 127.52, 129.3, 
131.5, 133.1, 133.9, 137.6; HR-MS (ESI+) m/z calculated for C18H16N3
+ = [M+H+]: 274.1339; found: 
274.1326. 
2-Methyl-7,11b-dihydro-6H-imidazo[1,5-a]isoquinolino[1,2-c]quinoxaline (3b): Brown solid (45 mg, 
67%); mp 177−180 oC; IR (MIR-ATR, 4000−600 cm-1): νmax  = 3055, 2924, 2858, 1705, 1513, 1360, 816, 
736, 651; 1H NMR (400 MHz, CDCl3) δ ppm = 2.32 (s, 3H), 2.82−2.87 (m, 1H), 3.19−3.24 (m, 1H), 
3.28−  3.35 (m, 1H), 3.87−3.92 (m, 1H), 5.45 (s, 1H), 6.94−6.96 (m, 2H), 7.01 (d, J = 1.5 Hz, 1H), 
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7.13−7.16 (m, 1H), 7.19−7.22 (m, 2H), 7.24−7.25 (m, 1H), 7.30−7.33 (m, 1H), 7.97 (d, J = 1 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 20.7, 27.1, 43.9, 54.9, 115.2, 116.3, 124.7, 124.8, 126.2, 126.9, 
127.3, 127.4, 127.7, 129.3, 129.8, 131.5, 133.1, 134.0, 135.4; HR-MS (ESI+) m/z calculated for C19H18N3
+ 
= [M+H+]: 288.1495; found: 288.1482. 
10-Bromo-7,11b-dihydro-6H-imidazo[1,5-a]isoquinolino[1,2-c]quinoxaline (3c): Brown solid (56 mg, 
68%); 168−170 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3049, 2922, 1718, 1604, 1509, 1475, 1347, 
1273, 813, 739, 651; 1H NMR (400 MHz, CDCl3) δ ppm = 2.78−2.82 (m, 1H), 3.2 (ddd, Ja = 16.9, Jb = 
11.5 and Jc = 5.9 Hz, 1H), 3.42 (ddd, Ja = 13.2, Jb = 11.7 and Jc = 4.4 Hz, 1H), 4.02−4.07 (m, 1H), 5.56 (s, 
1H), 6.92 (td, Ja = 7.7 and Jb = 1.2 Hz, 1H), 7.00−7.05 (m, 3H), 7.17−7.20 (m, 1H), 7.32 (dd, Ja = 8.3 and 
Jb = 1.5 Hz, 1H), 7.41−7.45 (m, 2H), 8.03 (d, J = 1 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 25.8, 
43.9, 54.6, 114.8, 115.8, 119.8, 119.9, 124.4, 125.2, 126.1, 127.0, 129.7, 130.6, 131.0, 131.7, 132.9, 
135.8, 136.7; HR-MS (ESI+) m/z calculated for C18H15BrN3
+ = [M+H+]: 352.0444; found: 352.0430.  
7,11b-Dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-c]quinoxaline (3d): Brown solid (45 mg, 71%) mp 
120−122 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3052, 2902, 2829, 1506, 1337, 1288, 1221, 738, 701, 
643; 1H NMR (400 MHz, CDCl3) δ ppm = 2.8 (d, J = 16.1 Hz, 1H), 3.19−3.27 (m, 1H), 3.31−3.38 (m, 
1H), 3.90−3.95 (m, 1H), 5.46 (s, 1H), 6.07−6.08 (m, 1H), 6.32−6.34 (m, 1H), 6.84−6.88 (m, 1H), 
6.97−6.99 (m, 1H), 7.05−7.20 (m, 5H), 7.31−7.34 (m, 2H); 13C NMR (100 MHz, CDCl3) δ ppm = 27.1, 
44.0, 56.2, 105.7, 110.0, 114.5, 115.1, 115.1, 119.7, 125.0, 126.0, 127.0, 127.5, 127.7, 128.5, 129.2, 
134.2, 134.4, 137.6; HR-MS (ESI+) m/z calculated for C19H17N2
+ = [M+H+]: 273.1386; found: 273.1382. 
10-Methyl-7,11b-dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-c]quinoxaline (3e): Brown solid (38 mg, 
60%); mp 130−132 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3044, 2918, 2847, 1505, 1337, 1289, 1164, 
741, 701, 610, 549; 1H NMR (400 MHz, CDCl3) δ ppm = 2.29 (s, 3H), 2.78 (d, J = 15.7 Hz, 1H), 
3.17−3.25 (m, 1H), 3.34 (td, Ja = 12 and Jb = 3.9 Hz, 1H), 3.9−3.96 (m, 1H), 5.44 (s, 1H), 6.09 (d, J = 2.9 
Hz, 1H), 6.34 (t, J = 3.2 Hz, 1H), 6.85−6.89 (m, 1H), 6.98−7.03 (m, 2H), 7.05−7.09 (m, 1H), 7.14 (s, 1H), 
7.17 (dd, Ja = 2.7 and Jb = 1.7 Hz, 1H), 7.23 (s, 1H), 7.33 (dd, J = 7.8 Hz, 1H). 
13C NMR (100 MHz, 
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CDCl3) δ ppm = 21.3, 26.6, 44.1, 56.14, 105.7, 110.0, 114.4, 115.0, 115.1, 119.6, 124.9, 127.6, 127.8, 
128.5, 129.0, 131.0, 134.1, 135.5, 137.6; HR-MS (ESI+) m/z calculated for C20H19N2
+ = [M+H+]: 
287.1543; found: 287.1539. 
10-Bromo-7,11b-dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-c]quinoxaline (3f): Brown solid (44 mg, 
73%); m.p. 148−150 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3048, 2919, 2833, 1508, 1340, 1165, 741, 
703, 657, 538; 1H NMR (400 MHz, CDCl3) δ ppm =  2.75 (d, J = 17.6, 1H), 3.16−3.24 (m, 1H), 3.38 
(ddd, Ja = 13.1, Jb = 11.6 and Jc = 4.2 Hz, 1H), 3.99 (ddd, Ja= 13.2, Jb = 5.6 and Jc = 2.2 Hz, 1H), 5.47 (s, 
1H), 6.13 (dd, Ja = 3.2 and Jb = 1.2 Hz, 1H), 6.36 (t, J = 3.2 Hz, 1H), 6.87 (td, Ja = 7.6 and Jb = 1.5 Hz, 
1H), 6.96−6.99 (m, 2H), 7.05−7.09 (m, 1H), 7.18 (dd, Ja = 2.9 and Jb = 1.5 Hz, 1H), 7.26−7.29 (m, 1H), 
7.32 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H), 7.42 (d, J = 1 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 
25.9, 44.1, 56.0, 106.2, 110.2, 114.5, 115.1, 115.2, 119.5, 119.8, 125.0, 127.0, 127.5, 130.1, 130.2, 130.8, 
133.0, 136.7, 137.1; HR-MS (ESI+) m/z calculated for C19H16BrN2
+ = [M+H+]: 351.0491; found: 
351.0477. 
7, 11b-Dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (3g): White solid (56 mg, 87%); mp 
88−90 oC; IR (MIR-ATR, 4000−600 cm-1) νmax = 3067, 2922, 2854, 1720, 1655, 1614, 1489, 1387, 1295, 
1238, 1119, 1031, 749, 697, 649; 1H NMR (400 MHz, CDCl3) δ ppm = 2.94 (dt, Ja = 16.6 and  Jb = 4.4 
Hz, 1H), 3.19−3.27 (m, 1H), 3.53−3.61 (m, 1H), 3.92−3.98 (m, 1H), 6.88 (s, 1H), 7.08 (td, J = 7.6 Hz, 
1H), 7.14−7.17 (t, J = 7.6 Hz, 2H), 7.20−7.22 (m, 1H), 7.28−7.35 (m, 2H ), 7.47 (ddd, Ja = 8.4, Jb = 7.2 
and Jc = 1.5 Hz, 1H), 8.03 (dd, Ja = 7.6 and Jb = 1.7 Hz, 1H ); 
13C NMR (100 MHz, CDCl3) δ ppm = 25.8, 
44.8, 72.0, 111.5, 116.2, 121.9, 126.3, 126.8, 127.7, 129.3, 129.4, 129.8, 133.4, 134.5, 143.7, 148.8; HR-
MS (ESI+) m/z calculated for C16H14N5
+ = [M+H+]: 276.1244; found: 276.1239.  
10-Methyl-7,11b-dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (3h): White solid (43 mg, 
68%); mp 170−172 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 2920, 1618, 1494, 1303, 1214, 1144, 1064, 
747, 612; 1H NMR (400 MHz, CDCl3) δ ppm = 2.28 (s, 3H), 2.89 (dt, Ja = 16.9 and Jb = 4 Hz, 1H), 
3.22(ddd, Ja = 16.5, Jb = 10.6 and Jc = 5.6 Hz, 1H), 3.54−3.61 (m, 1H), 3.95−4.01 (m, 1H), 6.89 (s, 1H), 
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7.04−7.15 (m, 5H), 7.45−7.49 (m, 1H), 8.04 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, 
CDCl3) δ ppm = 21.1, 25.3, 44.9, 72.1, 111.4, 115.9, 121.7, 126.4, 127.9, 129.2, 129.8, 130.3, 131.2, 
133.4, 136.6, 143.6, 148.8; HR-MS (ESI+) m/z calculated for C17H16N5
+ = [M+H+]: 290.1400; found: 
290.1395.  
10-Bromo-7,11b-dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (3i): white solid (46 mg, 
75%); 192−195 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 1618, 1580, 1488, 1304, 1220, 1139, 816, 739; 
1H NMR (400 MHz, CDCl3) δ ppm = 2.91 (dt, Ja = 17.1 and Jb = 3.9 Hz, 1H), 3.21 (ddd, Ja = 16.6, Jb = 
10.5 and Jc = 5.6 Hz, 1H), 3.59 (ddd, Ja = 14.4, Jb = 10 and Jc = 4.9 Hz, 1H), 3.99−4.05 (m, 1H), 6.91 (s, 
1H), 7.05 (d, J = 8.3, 1H), 7.09−7.16 (m, 2H), 7.41−7.52 (m, 3H), 8.06 (dd, Ja = 7.6 and Jb = 1.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 25.1, 44.6, 71.4, 111.3, 116.0, 120.3, 122.1, 126.5, 130.4, 131.0, 
132.1, 132.6, 133.3, 133.6, 143.1, 148.7; HR-MS (ESI+) m/z calculated for C16H13BrN5
+ = [M+H+]: 
354.0349; found: 354.0343.  
6,17a-Dihydro-5H-benzo[4,5]imidazo[1,2-c]isoquinolino[2,1-a]quinazoline (3j): White solid (49 mg, 
65%); m.p. 188−190 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3054, 2921, 2851, 1613, 1479, 1449, 
1226, 736, 642, 546; 1H NMR (400 MHz, CDCl3) δ ppm = 2.86 (d, J = 17.1 Hz, 1H), 3.45−3.62 (m, 1H), 
3.76−3.81 (m, 1H), 4.32−4.45 (m, 1H), 7.16−6.74 (m, 7H), 7.47−7.25 (m, 4H), 7.88−7.86 (m, 1H), 8.14 
(d, J = 7.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 23.8, 44.9, 69.5, 109.3, 119.7, 123.0, 123.2, 
125.6, 126.2, 126.6, 128.7, 129.5, 131.9, 134.3, 134.2, 134.5, 135.45, 143.8; HR-MS (ESI+) m/z 
calculated for C22H18N3
+ = [M+H+]: 324.1495; found: 324.1494.  
2-Methyl-6,17a-dihydro-5H-benzo[4,5]imidazo[1,2-c]isoquinolino[2,1-a]quinazoline (3k): White solid 
(36 mg, 48%); m.p. 178−180 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3049, 2920, 2851, 1613, 1479, 
1267, 1218, 736, 699, 641, 543; 1H NMR (400 MHz, CDCl3) δ ppm = 2.04 (s, 3H), 2.83 (d, J = 14.7 Hz, 
1H), 3.44−3.46 (m, 1H), 3.78−3.82 (m, 1H), 4.27−4.31 (m, 1H), 6.51−6.54 (m, 1H), 6.84−7.05 (m, 5H), 
7.32−7.42 (m, 4H), 7.88 (d, J = 7.3 Hz, 1H), 8.14 (d, J = 7.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
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ppm = 21.1, 23.5, 44.8, 69.3, 108.0, 109.1, 113.1, 119.5, 122.8, 123.0, 126.1, 129.3, 129.4, 131.8, 134.5, 
136.3, 143.7; HR-MS (ESI+) m/z calculated for C23H20N3
+ = [M+H+]: 338.1652; found: 338.1650.  
5-(Phenylamino)-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3l): White solid (50 
mg, 62%); mp 196−198 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3260, 3032, 2922, 2853, 1655, 1599, 
1472, 1267, 741, 697; 1H NMR (400 MHz, CDCl3) δ ppm = 2.75 (dd, Ja = 16.9 and Jb = 4.6, 1H), 
3.26−3.35 (m, 1H), 3.65 (ddd, Ja = 14.4, Jb = 12 and Jc = 5.4 Hz, 1H), 4.25 (dd, Ja = 14.4 and Jb = 5.1 Hz, 
1H), 5.98 (s, 1H), 6.84−6.87 (m, 1H), 6.92 (t, J = 7.3 Hz, 1H), 7.01−7.04 (m, 4H), 7.09−7.15 (m, 2H), 
7.22−7.26 (m, 2H), 7.31 (s, 1H), 7.38−7.42 (m, 1H), 7.53 (d, J = 7.3 Hz, 1H), 7.9 (dd, Ja = 7.8 and Jb = 
1.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 24.4, 44.8, 75.1, 113.6, 114.2, 117.2, 119.5, 121.8, 
126.2, 126.4, 128.2, 129.0, 129.3, 129.4, 134.0, 134.2, 135.3, 146.7, 147.5, 163.1; HR-MS (ESI+) m/z 
calculated for C22H20N3O
+ = [M+H+]: 342.1601; found: 342.1595. 
8-Chloro-5-(phenylamino)-12, 13-dihydro-4bH-isoquinolino[2, 1-a]quinazolin-6(5H)-one (3m): White 
solid (48 mg, 55%); mp 125−127 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3263, 2916, 2754, 1657, 
1488, 1248, 1099, 900, 739, 691, 643, 591; 1H NMR (400 MHz, CDCl3) δ ppm = 2.74 (dd, Ja = 16.9 and 
Jb = 4.6 Hz, 1H), 2.72−2.77 (m, 1H), 3.22−3.31 (m, 1H), 3.61−3.68 (m, 1H), 4.17−4.22 (m, 1H), 5.96 (s, 
1H), 6.92−6.93 (m, 2H), 6.99−7.02 (m, 2H), 7.11−7.22 (m, 2H), 7.23−7.25 (m, 2H), 7.31−7.34 (m, 1H), 
7.44 (br. s, 1H), 7.53 (d, J = 7.3 Hz, 1H), 7.86−7.87 (m, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 24.3,  
45.0, 75.2, 114.1, 115.1, 118.4, 121.8, 124.8, 126.3, 126.4, 128.4, 128.9, 129.0, 129.4, 133.8, 133.9, 
135.0, 146.1, 146.5, 162.1; HR-MS (ESI+) m/z calculated for C22H19ClN3O
+ = [M+H+]: 376.1211; found: 
376.1204.  
5-Phenyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3n): White solid (54 mg, 70%); 
mp 92−94 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3065, 1667, 1598, 1462, 1378, 1326, 1275, 755, 
695, 662; 1H NMR (400 MHz, CDCl3) δ ppm = 2.83 (dd, Ja = 17.1 and Jb = 4.4, 1H), 3.26−3.29 (m, 1H), 
3.72 (ddd, Ja = 14.7, Jb = 11.2 and  Jc = 5.9 Hz, 1H), 4.20−4.26 (m, 1H), 6.16 (s, 1H), 6.85−6.89 (m, 1H), 
6.98 (d, J = 8.3 Hz, 1H), 7.03−7.08 (m, 2H), 7.13−7.16 (m, 1H), 7.19−7.23 (m, 1H), 7.32−7.40 (m, 4H), 
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7.48−7.50 (m, 2H), 7.99 (dd, Ja = 7.8 and Jb = 2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 24.6, 
45.1, 75.3, 114.1, 119.2, 119.7, 125.1, 125.9, 126.2, 127.2, 128.2, 128.9, 129.1, 129.9, 133.8, 134.4, 
135.6, 141.7, 147.4, 162.8; HR-MS (ESI+) m/z calculated for C22H19N2O
+ = [M+H+]: 327.1492; found: 
327.1486.   
5-Benzyl-12, 13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)- one (3o): White solid (52 mg, 
65%); mp 158−160 oC; IR (MIR-ATR, 4000−600 cm-1): νmax  = 3030, 2917, 1648, 1601, 1475, 1261, 744, 
697; 1H NMR (400 MHz, CDCl3) δ ppm = 2.29 (dd, Ja = 16.9 and Jb = 3.7 Hz, 1H), 3.13−3.04 (m, 1H), 
3.48 (ddd, Ja = 14.1, Jb = 11.1 and Jc = 5.6 Hz, 1H), 3.98 (dd, Ja = 13.7 and Jb = 5.4 Hz, 1H), 4.36 (d, J = 
15.2 Hz, 1H), 5.72−5.85 (m, 2H), 6.82−6.88 (m, 2H), 6.99−7.01 (m, 1H), 7.13−7.19 (m, 2H), 7.22−7.35 
(m, 7H), 7.95 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm =  24.5, 44.6, 49.7, 
71.7, 113.7, 118.5, 119.4, 119.8, 125.9,  126.2, 127.5, 127.7, 128.3, 128.7, 129.3, 129.5, 133.4, 134.8, 
137.3, 147.5, 163.5; HR-MS (ESI+) m/z calculated for C23H21N2O
+ = [M+H+]: 341.1648; found: 341.1644.    
5-Benzyl-8-chloro-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3p): White solid (48 
mg, 55%); mp 210−212 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3062, 2920, 1652, 1476, 1259, 737, 
699, 639; 1H NMR (400 MHz, CDCl3) δ ppm = 2.71 (dd, Ja = 17.1 and Jb = 3.9 Hz, 1H), 3.03−3.11 (m, 
1H), 3.5 ( ddd, Ja = 14.2, Jb = 11 and Jc = 5.6 Hz, 1H), 3.95 (dd, Ja = 13.7 and Jb = 5.4 Hz, 1H), 4.35 (d, J 
= 15.2 Hz, 1H), 5.64−5.68 (m, 2H), 6.82 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 6.8 Hz, 1H), 7.15−7.21 (m, 2H), 
7.23−7.32 (m, 7H), 7.91 (d, J = 2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 24.4, 44.7, 49.8, 71.7, 
104.9, 109.8, 115.2, 124.7, 125.8, 126.4, 127.6, 127.7, 128.5, 128.7, 129.1, 129.3, 133.3, 134.5, 136.9, 
146.0, 162.4; HR-MS (ESI+) m/z calculated for C23H20ClN2O
+ = [M+H+]: 375.1259; found: 375.1250. 
5-Benzyl-3-methyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3q): White solid (47 
mg, 60%); mp 158−160 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3032, 2917, 1647, 1603, 1476, 1384, 
1264, 1169, 818, 738, 698; 1H NMR (400 MHz, CDCl3) δ ppm = 2.27 (s, 3H), 2.66 (dd, Ja = 16.6 and Jb = 
4.4 Hz, 1H), 3.08 (d, J = 6.4 Hz, 1H), 3.49 (ddd, Ja = 14.2, Jb = 11.2 and Jc = 5.9 Hz, 1H), 4.01 (dd, Ja = 
13.9 and Jb = 5.6 Hz, 1H), 4.34 (d, J = 15.7 Hz, 1H), 5.64 (s, 1H), 5.74 (s, 1H), 6.83−6.92 (m, 3H), 6.99− 
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7.02 (m, 2H), 7.27−7.34 (m, 6H), 7.97 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 
ppm = 21.2, 24.1, 44.7, 49.9, 71.8, 113.6, 118.4, 119.3, 126.4, 127.5, 127.7, 128.7, 129.0, 129.1, 129.5, 
131.6, 133.4, 135.8, 137.3, 147.5, 163.5; HR-MS (ESI+) m/z calculated for C24H23N2O
+ = [M+H+]: 
355.1805; found: 355.1799. 
5-Benzyl-8-chloro-3-methyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3r): White 
solid (41 mg, 48%); mp 152−155 oC; 48% yield; IR (MIR-ATR, 4000−600 cm-1): νmax = 2912, 2753, 
1649, 1454, 1255, 1103, 889, 809, 732, 698, 640, 589, 539; 1H NMR (400 MHz, CDCl3) δ ppm = 2.27 (s, 
3H), 2.66 (dd, J = 16.9 and 4.6, 1H), 3.01−3.09 (m, 1H), 3.48 (ddd, Ja = 14.2, Jb = 11.2 and Jc = 5.9 Hz, 
1H), 3.94 (dd, Ja = 13.7 and Jb = 5.9 Hz, 1H), 4.32 (d, J = 15.2 Hz, 1H), 5.61 (s, 1H), 5.72 (d, J = 12.2 
Hz, 1H), 6.8 (d, J = 8.8 Hz, 1H), 6.9−6.92 (m, 1H), 6.99−7.01 (m, 2H), 7.24−7.33 (m, 6H), 7.91 (d, J = 
2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm =  21.2, 24.0, 44.8, 50.0, 71.8, 115.1, 119.6, 124.6, 
126.3, 127.6, 127.7, 128.7, 129.1, 129.2, 129.3, 131.3, 133.2, 136.0, 137.0, 146.0, 162.4; HR-MS (ESI+) 
m/z calculated for C24H22ClN2O
+ = [M+H+]: 389.1415; found: 389.1408. 
5-Benzyl-3-bromo-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (3s): White solid (43 
mg, 62%); 128−130 oC; IR (MIR-ATR, 4000−600 cm-1) νmax = 3340, 3057, 2919, 1647, 1603, 1477, 1260, 
1167, 816, 734, 697, 629, 546; 1H NMR (400 MHz, CDCl3) δ ppm = 2.64 (dd, Ja = 17.1 and Jb = 4.9 Hz, 
1H), 3.07−3.11 (m, 1H), 3.5 (ddd, Ja = 14.4, Jb = 11.5 and Jc = 5.9 Hz, 1H), 4.07 (dd, Ja = 14.2 and Jb = 
5.9 Hz, 1H), 4.3 (d, J = 15.7 Hz, 1H), 5.6 (s, 1H), 5.81 (d, J = 15.2 Hz, 1H), 6.86−6.89 (m, 3H), 
7.26−7.36 (m, 8H), 7.96 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 23.6, 
44.3, 50.1, 71.4, 113.4, 118.2, 119.6, 119.9, 127.6, 127.7, 128.6, 128.8, 129.62, 130.9, 131.4, 133.5, 
133.6, 136.9, 146.9, 163.1; HR-MS (ESI+) m/z calculated for C23H20BrN2O
+ = [M+H+]: 419.0754; found: 
419.0746. 
4b,5,12,13-Tetrahydrobenzo[5,6]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3t): White solid (47 mg, 
70%); mp 218−220 oC; 70% yield; IR (MIR-ATR, 4000−600 cm-1): νmax =  3231, 2922, 2853, 1597, 1481, 
1449, 1318, 1274, 1158, 748, 662, 610, 556; 1H NMR (400 MHz, CDCl3) δ ppm = 2.98−3.14 (m, 2H), 
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3.46 (ddd, Ja = 12.3, Jb = 8.2 and Jc = 4.4 Hz, 1H), 3.86 (dt, Ja = 12.5 and  Jb = 5.3 Hz, 1H), 4.77 (d, J = 
12.7 Hz, 1H), 5.98 (d, J = 13.2 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.3 Hz, 1H), 7.20−7.23 (m, 
1H), 7.30−7.33 (m, 2H), 7.45 (ddd, Ja = 8.6, Jb = 7.1 and Jc = 1.5 Hz, 1H), 7.6 (dd, Ja = 5.4 and Jb = 3.9 
Hz, 1H), 7.78 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 43.8, 68.5, 
116.1, 119.4, 125.3, 125.4, 127.1, 127.7, 128.3, 128.7, 131.7, 133.5, 135.0, 144.5; HR-MS (ESI+) m/z 
calculated for C15H15N2O2S
+ = [M+H+]: 287.0849; found: 287.0845. 
8-Chloro-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3u): White 
solid (69 mg, 90%); mp 198−200 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3222, 3065, 2925, 2849, 
1597, 1478, 1322, 1160, 734, 666, 621, 554; 1H NMR (400 MHz, CDCl3) δ ppm = 3.0−3.1 (m, 2H), 3.46 
(ddd, Ja = 12.2, Jb = 8.1 and Jc = 4.6 Hz, 1H), 3.78−3.84 (m, 1H), 4.93 (d, J = 12.7 Hz, 1H), 5.95 (d, J = 
12.7 Hz, 1H), 7.0 (d, J = 8.8 Hz, 1H), 7.21−7.23 (m, 1H), 7.31−7.38 (m, 3H), 7.57 (dd, Ja = 5.1 and Jb = 
3.7 Hz, 1H), 7.7 (d, J = 2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 28.9, 44.0,  68.3, 117.8, 
124.3, 124.7, 125.9 , 127.2, 127.7, 128.3, 128.8, 131.2, 133.6, 134.8, 143.1; HR-MS (ESI+) m/z calculated 
for C15H14ClN2O2S
+ = [M+H+]: 321.0459; found: 321.0454.  
8-Bromo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3v): White 
solid (70 mg, 82%); mp 200−202 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3411, 3027, 2837, 2720, 
2253, 2128, 1644, 1593, 1476, 1322, 1164, 1005, 820, 758, 617, 561; 1H NMR (400 MHz, CDCl3) δ ppm 
= 2.98−3.10 (m, 2H), 3.43−3.47 (td, Ja = 8.2 and Jb = 4.2 Hz, 1H), 3.78−3.83 (m, 1H), 4.95 (d, J = 12.7 
Hz, 1H), 5.93 (d, J = 12.7 Hz, 1H), 6.93 (d, J = 9.3 Hz, 1H), 7.21−7.24 (m, 1H), 7.30−7.35 (m, 2H), 
7.47−7.5 (m, 1H), 7.54−7.57 (m, 1H), 7.82 (d, J = 2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 
28.9, 43.9, 68.4, 111.2, 117.8, 126.3, 127.3, 127.6, 127.8, 128.3, 128.9, 131.2, 134.8, 136.4, 143.4; HR-
MS (ESI+) m/z calculated for C15H14BrN2O2S
+ = [M+H+]: 364.9954; found: 364.9948. 
8-Iodo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3w): White 
solid (76 mg, 79%); mp 210−212 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3419, 1649, 1402, 1175, 
1006, 821, 759, 618, 568; 1H NMR (400 MHz, CDCl3) δ ppm = 2.55−2.61 (m, 1H), 2.96−3.13 (m, 1H), 
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3.47 (ddd, Ja = 12.1, Jb = 7.5 and Jc = 4.4 Hz, 1H), 3.77−3.83 (m, 1H), 5.9 (d, J = 12.2 Hz, 1H), 6.84 (d, J 
= 8.8 Hz, 1H), 7.20−2.22 (m, 1H), 7.29−7.38 (m, 2H), 7.55−7.57 (m, 1H), 7.64 (dd, Ja = 8.8 and Jb = 2 
Hz, 1H), 7.98 (d, J = 2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 28.9, 43.8, 68.3, 79.9, 117.9, 
126.7, 127.3, 127.6, 128.3, 128.9, 131.3, 133.4, 134.8, 142.0, 143.9; HR-MS (ESI+) m/z calculated for 
C15H14IN2O2S
+ = [M+H+]: 412.9815; found: 412.9809. 
3-Methyl-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3x): White 
solid (41 mg, 62%); mp 228−230 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3205, 2918, 2851, 1715, 
1594, 1450, 1319, 1156, 741, 664, 559; 1H NMR (400 MHz, CDCl3) δ ppm = 2.36 (s, 3H), 2.96−3.04 (m, 
2H), 3.42 (ddd, Ja = 12.3, Jb = 8.2 and Jc = 4.2 Hz, 1H), 3.83 (dt, Ja = 12.1 and Jb = 5.2 Hz, 1H), 4.78 (d, J 
= 12.7 Hz, 1H), 5.92 (d, J = 13.2 Hz, 1H), 6.94−6.96 (m, 1H), 7.05−7.14 (m, 3H), 7.40−7.46 (m, 2H), 
7.76 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 28.6, 43.9, 68.6, 
116.1, 119.4, 125.3, 125.4, 128.2, 129.6, 131.4, 131.8, 133.5, 136.9, 144.6; HR-MS (ESI+) m/z calculated 
for C16H17N2O2S
+ = [M+H+]: 301.1005; found: 301.1001. 
8-Iodo-3-methyl-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3y): 
White solid (64 mg, 68%); mp 218−220 oC; IR (MIR-ATR, 4000−600 cm-1): νmax  = 3217, 2921, 2854, 
1469, 1322, 1273, 1160, 929, 798, 730, 665; 1H NMR (400 MHz, CDCl3) δ ppm = 2.36 (s, 3H), 2.92− 
3.05 (m, 2H), 3.41 (ddd, Ja = 12.3, Jb = 8.4 and Jc = 4.2 Hz, 1H), 3.78−3.83 (m, 1H), 4.88 (d, J = 12.7 Hz, 
1H), 5.9 (d, J = 12.7 Hz, 1H), 6.81 (d, J = 9.3 Hz, 1H), 7.09−7.14 (m, 2H), 7.38 (s, 1H), 7.66 (dd, Ja = 8.8 
and Jb = 2 Hz, 1H), 7.99 (d, J = 2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 28.5, 43.9, 68.4, 
79.9, 117.9, 126.7, 128.0, 128.2, 129.7, 131.0, 131.7, 133.5, 137.1, 142.0, 143.9; HR-MS (ESI+) m/z 
calculated for C16H16IN2O2S
+ = [M+H+]: 426.9972; found: 426.9962.   
3-Bromo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3z): White 
solid (54 mg, 65%); mp 228−230 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3213, 2924, 2852, 1706, 
1598, 1478, 1319, 1161, 738, 548; 1H NMR (400 MHz, CDCl3) δ ppm = 2.90−2.96 (m, 2H), 3.36 (ddd, Ja 
= 12.5, Jb = 7.8 and Jc = 4.6 Hz, 1H), 3.74−3.79 (m, 1H), 4.83 (d, J = 12.7 Hz, 1H), 5.81 (d, J = 13.2 Hz, 
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1H), 6.87−6.92 (m, 1H), 7.01 (dd, Ja = 10.3 and Jb = 8.8 Hz, 2H), 7.34−7.40 (m, 2H), 7.64−7.67 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ ppm = 28.6, 43.7, 67.9, 116.4, 119.8, 120.7, 125.4, 125.5, 130.0, 130.7, 
131.9, 133.6, 133.9, 144.2; HR-MS (ESI+) m/z calculated for C15H14BrN2O2S
+ = [M+H+]: 364.9954; 
found: 364.9951. 
4b,6,12,13-Tetrahydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinoline (3aa): White solid (33 mg, 60%); mp 
115−117 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 3035, 2933, 2897, 2838, 1602, 1491, 1455, 1389, 
1287, 1228, 1193, 1154, 1056, 1029, 946, 749, 664; 1H NMR (400 MHz, CDCl3) δ ppm = 2.91 (dt, Ja = 
15.9 and Jb = 3.5 Hz, 1H), 3.14 (ddd, Ja = 16, Jb = 10.6 and Jc = 5.1 Hz, 1H), 3.44−3.58 (m, 2H), 4.96 (d, 
J = 15.2 Hz, 1H), 5.22 (d, J = 14.7 Hz, 1H), 5.41 (s, 1H), 6.95−7.02 (m, 2H), 7.11 (d, J = 7.8 Hz, 1H), 
7.17−7.28 (m, 4H), 7.45 (dd, Ja= 5.4 and Jb = 3.9 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ ppm = 29.8, 
46.2, 68.3, 84.4, 121.2, 121.7, 1245.0, 126.3, 126.4, 127.3, 128.3, 128.7, 133.4, 135.3, 146.0; HR-MS 
(ESI+) m/z calculated for C16H14N
+ = [[M+H+]-H2O]: 220.1120; found: 220.1113. 
12,13-Dihydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinolin-6(4bH)-one (3ab): White solid (43 mg, 72%); 
mp 115−117 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 1720, 1607, 1484, 1467, 1399, 1331, 1292, 1229, 
752; 1H NMR (400 MHz, CDCl3) δ ppm =  3.1 (t, Ja = 5.9, Jb = 5.9 Hz, 2H), 3.46−3.52 (m, 1H), 3.71− 
3.76 (m, 1H), 6.14 (s, 1H), 7.11−7.13 (m, 2H), 7.26−7.24 (m, 1H), 7.33−7.36 (m, 2H), 7.55−7.59 (m, 
2H), 8.11 (dd, J = 7.8 Hz, 1.5, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 43.6, 85.7, 117.0, 117.2, 
122.0, 127.0, 128.4, 128.6, 129.3, 130.0, 131.0, 134.7, 135.1, 150.0, 165.1; HR-MS (ESI+) m/z calculated 
for C16H14NO2
+ = [M+H+]: 252.1019; found: 252.1008. 
6-Phenyl-4b,6,12,13-tetrahydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinoline (3ac): brown solid (35 mg, 
52%); mp 60−62 oC ; IR (MIR-ATR, 4000-600 cm-1): νmax  = 3029, 2925, 2834, 1659, 1601, 1487.44, 
1455, 1391, 1221, 1146, 939, 747, 699, 644; 1H NMR (400 MHz, CDCl3) δ ppm = 2.85−2.99 (m, 2H), 
3.18−3.23 (m, 2H), 3.55−3.60 (m, 2H), 3.71−3.72 (m, 1H), 3.98 (t, J = 5.9 Hz, 1H), 5.36 (s, 1H), 5.68 (s, 
1H), 6.04 (s, 1H), 6.21 (s, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.85−6.88 (m, 1H), 6.97−7.05 (m, 3H), 
7.15−7.16 (m, 4H), 7.21−7.25 (m, 4H), 7.29−7.32 (m, 2H), 7.33−7.43 (m, 4H), 7.43−7.51 (m, 7H); 13C, 
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HMBC, HSQC NMR (100 MHz, CDCl3) δ ppm = 29.7 (t, -CH2-), 29.9 (t, -CH2-), 46.1 (t, -CH2-), 47.0 (t, 
-CH2-), 77.07 (d, -CH-), 78.2 (d, -CH-), 81.5 (d, -CH-), 84.4 (d, -CH-), 120.9 (d, Ar-CH), 121.0 (d, Ar-
CH), 121.7 (s, Ar-C), 121.8 (d, Ar-CH), 122.0 (d, Ar-CH), 125.8 (s, Ar-C), 126.3 (d, Ar-CH), 126.4 (d, 
Ar-CH), 127.3 (d, Ar-CH), 127.6 (d, Ar-CH), 127.9 (d, Ar-CH), 128.0 (d, 2C, Ar-CH), 128.0 (d, 2C, Ar-
CH), 128.1 (d, Ar-CH), 128.2 (d, 2C, Ar-CH), 128.3 (s, Ar-C), 128.4 (d, 2C, Ar-CH), 128.5 (d, Ar-CH), 
128.5 (d, 2C, Ar-CH), 128.8 (d, 2C, Ar-CH), 129.1 (d, Ar-CH), 129.4 (d, 2C, Ar-CH), 130.3 (s, Ar-C), 
133.4 (s, Ar-C), 135.1 (s, Ar-C), 135.4 (s, Ar-C), 141.8 (s, Ar-C), 142.4 (s, Ar-C), 146.4 (s, Ar-C). 
12,12',13,13'-Tetrahydro-[5,5'-biisoquinolino[2,1-a]quinazoline]-6,6'(4bH,4'bH)-dione (3ae): White 
solid (45 mg, 38%); mp 230−232 oC; IR (MIR-ATR, 4000−600 cm-1): νmax = 2903, 1722, 1606, 1466, 
1398, 1294, 1241, 1160, 1119, 1032, 951, 750, 697, 639; 1H NMR (400 MHz, CDCl3) δ ppm = 2.90−2.93 
(m, 2H), 3.45−3.62 (m, 2H), 6.48 (s, 1H), 7.32−7.49 (m, 1H), 7.50−7.53 (m, 3H), 7.81−7.91 (m, 3H), 
8.33−8.35 (m, 1H); 13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 45.0, 72.7, 118.7, 120.3, 121.7, 125.9, 
127.7, 128.1, 128.9, 129.6, 130.6, 133.9, 136.4, 150.0, 166.6; HR-MS (ESI+) m/z calculated for 
C32H27N4O2
+ = [M+H+]: 499.2129; found: 499.2127. 
 Supporting Information  
Experimental procedures and characterization for all new compounds, copies of NMR spectra, and CIF 
files (for 3p, 3t and 3ae) provided. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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